You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 15, 2024

Claims for Patent: 8,771,648

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,771,648

Title:	(Trimethoxyphenylamino) pyrimidinyl formulations
Abstract:	There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them. ##STR00001##
Inventor(s):	Gururajan; Bindhumadhavan (Molndal, SE), Alhusban; Farhan Abdul Karim (Macclesfield, GB), Gabbott; Ian Paul (Macclesfield, GB), Simpson; David Bradley Brook (Macclesfield, GB), Sievwright; Dawn (Macclesfield, GB)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	13/559,805
Patent Claims:	1. A solid pharmaceutical composition comprising greater than 15% w/w of the compound of Formula (I): ##STR00006## wherein each X.sup.+ represents a monovalent cation; and/or a hydrate thereof; and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution at low pH; and further comprising one or more pharmaceutically acceptable ingredients. 2. The solid pharmaceutical composition according to claim 1 comprising greater than or equal to 25% w/w of the compound of Formula (I) and/or hydrate thereof. 3. The solid pharmaceutical composition according to claim 1 comprising less than or equal to 20% w/w of the effervescent agent. 4. The solid pharmaceutical composition according to claim 1 wherein the effervescent agent is sodium hydrogen carbonate. 5. The solid pharmaceutical composition according to claim 1 wherein each X.sup.+ in the compound of Formula (I) represents a sodium cation (Na.sup.+). 6. The solid pharmaceutical composition according to claim 1 wherein the compound of Formula (I) is in the form of an hexahydrate. 7. The solid pharmaceutical composition according to claim 1 wherein the compound of Formula (I) is in the form of Formula (II): ##STR00007## 8. A unit dosage form comprising greater than or equal to 60 mg of the compound of Formula (I): ##STR00008## wherein each X.sup.+ represents a monovalent cation; and/or a hydrate thereof; and less than or equal to 110 mg of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution at low pH; and further comprising one or more pharmaceutically acceptable ingredients.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.